Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 363

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Propionate attenuates atherosclerosis by immune-dependent regulation of intestinal cholesterol metabolism

Open access
Haghikia, Arash, Zimmermann, Friederike, Schumann, Paul, Jasina, Andrzej, Roessler, Johann, Schmidt, David, Heinze, Philipp, Kaisler, Johannes, Nageswaran, Vanasa, Aigner, Annette, Ceglarek, Uta, Cineus, Roodline, Hegazy, Ahmed N, van der Vorst, Emiel P C, Döring, Yvonne, Strauch, Christopher M, Nemet, Ina, Tremaroli, Valentina, Dwibedi, Chinmay, Kränkel, Nicolle, Leistner, David M, Heimesaat, Markus M, Bereswill, Stefan, Rauch, Geraldine, Seeland, Ute, Soehnlein, Oliver, Müller, Dominik N, Gold, Ralf, Bäckhed, Fredrik, Hazen, Stanley L, Haghikia, Aiden, Landmesser, Ulf·2022·European Heart Journal

Abstract

Aims: Atherosclerotic cardiovascular disease (ACVD) is a major cause of mortality and morbidity worldwide, and increased low-density lipoproteins (LDLs) play a critical role in development and progression of atherosclerosis. Here, we examined for the first time gut immunomodulatory effects of the microbiota-derived metabolite propionic acid (PA) on intestinal cholesterol metabolism. Methods and results: Using both human and animal model studies, we demonstrate that treatment with PA reduces blood total and LDL cholesterol levels. In apolipoprotein E−/− (Apoe −/−) mice fed a high-fat diet (HFD), PA reduced intestinal cholesterol absorption and aortic atherosclerotic lesion area. Further, PA increased regulatory T-cell numbers and interleukin (IL)-10 levels in the intestinal microenvironment, which in turn suppressed the expression of Niemann-Pick C1-like 1 (Npc1l1), a major intestinal cholesterol transporter. Blockade of IL-10 receptor signalling attenuated the PA-related reduction in total and LDL cholesterol and augmented atherosclerotic lesion severity in the HFD-fed Apoe −/− mice. To translate these preclinical findings to humans, we conducted a randomized, double-blinded, placebo-controlled human study (clinical trial no. NCT03590496). Oral supplementation with 500 mg of PA twice daily over the course of 8 weeks significantly reduced LDL [−15.9 mg/dL (−8.1%) vs. −1.6 mg/dL (−0.5%), P = 0.016], total [−19.6 mg/dL (−7.3%) vs. −5.3 mg/dL (−1.7%), P = 0.014] and non-high-density lipoprotein cholesterol levels [PA vs. placebo: −18.9 mg/dL (−9.1%) vs. −0.6 mg/dL (−0.5%), P = 0.002] in subjects with elevated baseline LDL cholesterol levels. Conclusion: Our findings reveal a novel immune-mediated pathway linking the gut microbiota-derived metabolite PA with intestinal Npc1l1 expression and cholesterol homeostasis. The results highlight the gut immune system as a potential therapeutic target to control dyslipidaemia that may introduce a new avenue for prevention of ACVDs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehab644

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 50 references

Cited by

See all 363

Metadata

Authors
Haghikia, A., Zimmermann, F., Schumann, P., Jasina, A., Roessler, J., Schmidt, D., Heinze, P., Kaisler, J., Nageswaran, V., Aigner, A., Ceglarek, U., Cineus, R., Hegazy, A. N., van der Vorst, E. P. C., Döring, Y., Strauch, C. M., Nemet, I., Tremaroli, V., Dwibedi, C., Kränkel, N., Leistner, D. M., Heimesaat, M. M., Bereswill, S., Rauch, G., Seeland, U., Soehnlein, O., Müller, D. N., Gold, R., Bäckhed, F., Hazen, S. L., Haghikia, A., & Landmesser, U.
Venue
European Heart Journal
Published
2021-10-01
Volume
43
Issue
6
Pages
518-533
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W3204736341
Cited by
363
References
50
FWCI
38.98
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Propionate attenuates atherosclerosis by immune-dependent regulation of intestinal cholesterol metabolism. https://app.cochat.ai/papers/10.1093/eurheartj/ehab644
The paper
Haghikia, A., Zimmermann, F., Schumann, P., Jasina, A., Roessler, J., Schmidt, D., Heinze, P., Kaisler, J., Nageswaran, V., Aigner, A., Ceglarek, U., Cineus, R., Hegazy, A. N., van der Vorst, E. P. C., Döring, Y., Strauch, C. M., Nemet, I., Tremaroli, V., Dwibedi, C., . . . Landmesser, U. (2022). Propionate attenuates atherosclerosis by immune-dependent regulation of intestinal cholesterol metabolism. European Heart Journal. https://doi.org/10.1093/eurheartj/ehab644

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.